Impact of special patient populations on the pharmacokinetics of echinocandins
Authors:
- Eline W MuilwijkEMEline W Muilwijk
- Vincent Jc LempersVLVincent Jc Lempers
- David M BurgerDBDavid M Burger
- Adilia WarrisAWAdilia Warris
- Peter PickkersPPPeter Pickkers
- Rob E AarnoutseRARob E Aarnoutse
- Roger Jm BrüggemannRBRoger Jm Brüggemann
- 1 April 2015
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 13 (6) , 799-815
Abstract
Echinocandins belong to the class of antifungal agents. Currently, three echinocandin drugs are licensed for intravenous treatment of invasive fungal infections: anidulafungin, caspofungin and micafungin. While their antifungal activity overlaps, there are substantial differences in pharmacokinetics (PK). Numerous factors may account for variability in PK of echinocandins including age (pediatrics vs adults), body surface area and body composition (normal weight vs obesity), disease status (e.g., critically ill and burn patients) and organ dysfunction (kidney and liver impairment). Subsequent effects of altered exposure might impact efficacy and safety. Knowledge of PK behavior is crucial in optimal clinical utilization of echinocandin in a specific patient or patient population. This review provides up-to-date information on PK data of anidulafungin, caspofungin and micafungin in special patient populations. Patient populations addressed are neonates, children and adolescents, obese patients, patients with hepatic or renal impairment, critically ill patients (including burn patients) and patients with hematological diseases.Keywords
This publication has 111 references indexed in Scilit:
- Improving antibiotic dosing in special situations in the ICUCurrent Opinion in Critical Care, 2012
- Pharmacokinetics of Caspofungin in Two Patients with Burn InjuriesAntimicrobial Agents and Chemotherapy, 2012
- Population Pharmacokinetics of Liposomal Amphotericin B and Caspofungin in Allogeneic Hematopoietic Stem Cell RecipientsAntimicrobial Agents and Chemotherapy, 2012
- Higher clearance of micafungin in neonates compared with adults: role of age‐dependent micafungin serum bindingBiopharmaceutics & Drug Disposition, 2011
- Safety and Pharmacokinetics of Multiple-Dose Anidulafungin in Infants and NeonatesClinical Pharmacology & Therapeutics, 2011
- Safety and Pharmacokinetics of Repeat-Dose Micafungin in Young InfantsClinical Pharmacology & Therapeutics, 2009
- Pharmacokinetics of an Elevated Dosage of Micafungin in Premature NeonatesThe Pediatric Infectious Disease Journal, 2009
- Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenationJournal of Antimicrobial Chemotherapy, 2009
- The Pharmacokinetics and Pharmacodynamics of Micafungin in Experimental HematogenousCandidaMeningoencephalitis: Implications for Echinocandin Therapy in NeonatesThe Journal of Infectious Diseases, 2008
- Population Pharmacokinetics of Micafungin in Pediatric Patients and Implications for Antifungal DosingAntimicrobial Agents and Chemotherapy, 2007